Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial - The Lancet Oncology
Trabectedin for advanced soft tissue sarcomas: a single institution experience | Future Oncology
Han WONG | Consultant Medical Oncologist | MB ChB, PhD, FRCP | Cambridge University Hospitals NHS Foundation Trust, Cambridge | Addenbrooke's Hospital | Research profile
Ioannis GOUNARIS | Merck, Darmstadt | Pharmaceuticals | Research profile
Ioannis GOUNARIS | Merck, Darmstadt | Pharmaceuticals | Research profile
Sarah HILBORNE | Senior Research Nurse | PG Cert Health Studies | University of Cambridge, Cambridge | Cam | Department of Medicine | Research profile
Ioannis GOUNARIS | Merck, Darmstadt | Pharmaceuticals | Research profile
Ioannis Gounaris | LinkedIn
Ioannis FLESSAS | Consultant | MD, MSc, PhD, FEBS, FACS | Henry Dunant Hospital, Athens | C Breast Clinic | Research profile
Ioannis Gounaris | LinkedIn
Ioannis GOUNARIS | Merck, Darmstadt | Pharmaceuticals | Research profile
Lesson of the month 2: Cauda equina in Cushing's syndrome | RCP Journals
Scientific Meeting “The Refugees of 1922”
Ioannis Gounaris | LinkedIn
Ioannis GOUNARIS | Merck, Darmstadt | Pharmaceuticals | Research profile
Ioannis Gounaris | LinkedIn
Ioannis Gounaris | LinkedIn
Ioannis Gounaris | LinkedIn
Ioannis Gounaris | LinkedIn
Ioannis Gounaris | LinkedIn
Ioannis GOUNARIS | Merck, Darmstadt | Pharmaceuticals | Research profile
Professor Steve Charnock-Jones
Ioannis Gounaris | LinkedIn
Ioannis Gounaris | LinkedIn
Ioannis Gounaris | LinkedIn
Ioannis GOUNARIS | Merck, Darmstadt | Pharmaceuticals | Research profile
